Dyskinesia in Parkinson’s disease refers to involuntary, uncontrollable movements that develop as a side effect of long-term levodopa therapy, the most effective medication for managing Parkinson’s symptoms. These movements can look like writhing, swaying, fidgeting, or head bobbing, and they typically emerge after years of treatment. About 30% of people on levodopa develop dyskinesia within five years, and that number climbs to roughly 59% by ten years of treatment.
The core irony of dyskinesia is that it’s caused by the same medication that provides the most relief from Parkinson’s stiffness and slowness. Understanding why it happens, what it looks and feels like, and how it can be managed makes a real difference in navigating life with Parkinson’s.
Why Levodopa Eventually Causes Dyskinesia
Parkinson’s disease destroys the brain cells that produce dopamine, a chemical messenger essential for smooth, coordinated movement. Levodopa works by supplying the brain with a precursor it can convert into dopamine. Early in treatment, the brain still has enough healthy cells to store and release this converted dopamine in a relatively steady way, so the medication works smoothly.
As the disease progresses and more dopamine-producing cells die off, the brain loses its ability to buffer and regulate the incoming dopamine from each dose. Instead of a steady supply, the brain experiences sharp spikes when medication is active and steep drops when it wears off. These fluctuations overstimulate the movement circuits in the brain, producing the involuntary movements we call dyskinesia. The longer someone takes levodopa and the more cells they lose, the narrower the “therapeutic window” becomes, meaning the gap between too little medication (stiffness returns) and too much (dyskinesia appears) shrinks over time.
The Three Types of Dyskinesia
Peak-Dose Dyskinesia
This is the most common form. It occurs when levodopa levels in the blood are at their highest, typically 30 to 90 minutes after taking a dose. The movements are often choreiform, a medical term for flowing, dance-like motions that can affect the arms, trunk, and face. Some people experience jerking movements, sustained muscle contractions, or even involuntary eye movements. In one study, 16% of people with advanced Parkinson’s had abnormal eye movements during peak medication periods that disappeared once the dose wore off. Peak-dose dyskinesia can last for hours. One documented case involved abdominal movements that started about 30 minutes after each dose and persisted for roughly three hours.
Off-Period Dyskinesia
Off-period dyskinesia happens at the opposite end of the cycle, when medication levels drop to their lowest. Rather than the flowing movements of peak-dose dyskinesia, this type usually shows up as painful muscle spasms, most often in a foot or leg. It’s especially common first thing in the morning, before the first dose kicks in, though it can appear at any point during the day when medication wears off between doses.
Diphasic Dyskinesia
The least common type, diphasic dyskinesia strikes twice per dose cycle: once as medication levels are rising and again as they’re falling. This creates a recognizable pattern of involuntary movement, then a window of good symptom control, then involuntary movement again. The movements tend to affect the legs and are often more sustained and cramping in character. Some people experience a mix of flowing and cramping movements together.
What Dyskinesia Looks and Feels Like
From the outside, dyskinesia can range from barely noticeable fidgeting to large, sweeping motions of the limbs and torso. Mild dyskinesia might look like slight rocking or swaying that the person isn’t fully aware of. Moderate to severe dyskinesia can make it difficult to sit still, hold objects, eat, or walk safely. Some people develop breathing irregularities when dyskinesia affects the muscles controlling respiration.
Many people with mild dyskinesia actually prefer it to the alternative. When the medication is working and dyskinesia is present, they can still move, think, and function, even if they’re fidgeting. When the medication wears off, stiffness and slowness return, which many find more disabling. The trade-off between “on with dyskinesia” and “off with immobility” is one of the central challenges of advanced Parkinson’s management.
Persistent involuntary movement also takes a physical toll over time. The constant muscle activity increases calorie expenditure, which can contribute to unintentional weight loss, fatigue, and difficulty maintaining adequate nutrition.
Who Is Most at Risk
Several factors influence how quickly dyskinesia develops. Younger age at Parkinson’s diagnosis is one of the strongest predictors. People diagnosed before age 50 tend to develop dyskinesia sooner than those diagnosed later in life, even though their overall disease course may be longer. Disease severity also matters: more advanced Parkinson’s at the time levodopa is started correlates with earlier onset of dyskinesia.
Interestingly, levodopa dose relative to body weight is a more significant risk factor than the absolute dose. A 120-pound person taking 600 mg of levodopa daily is at greater risk than a 200-pound person on the same dose. Female sex has also been identified as a risk factor, though it may not be fully independent from body weight differences.
How Dyskinesia Is Managed
The first approach is usually adjusting the levodopa regimen itself. Smaller, more frequent doses can reduce the sharp peaks and valleys in medication levels that trigger dyskinesia. Your neurologist may also add or adjust other Parkinson’s medications that smooth out levodopa’s effects or allow for a lower total dose.
Amantadine is the primary medication used specifically to treat dyskinesia. A meta-analysis found that people taking amantadine gained roughly half an hour of additional daily “on” time without troublesome dyskinesia, while their time spent in the “on” state with significant involuntary movements decreased by a similar amount. Dosing typically starts low, around 100 mg per day, and may be increased to 200 to 400 mg daily. Several formulations exist, including extended-release versions designed to provide more consistent coverage.
Dietary Strategies
Protein competes with levodopa for absorption in the gut, so what you eat and when you eat it can affect how much medication actually reaches the brain. For people experiencing motor fluctuations and dyskinesia, two dietary approaches are commonly used: a low-protein diet that reduces total daily protein intake, and a protein redistribution diet that shifts most protein consumption to the evening meal, keeping daytime levodopa absorption more predictable. Both strategies can improve levodopa’s consistency, but they require careful planning to avoid nutritional deficiencies and further weight loss.
Deep Brain Stimulation
For people with significant dyskinesia that can’t be adequately controlled with medication adjustments, deep brain stimulation (DBS) is an option. This surgical procedure involves implanting thin electrodes in specific areas of the brain that regulate movement. Electrical pulses from these electrodes help stabilize the overactive circuits responsible for dyskinesia. DBS can reduce the need for high levodopa doses, which in turn reduces dyskinesia. The FDA first approved DBS for advanced Parkinson’s in 2002, then expanded approval in 2016 to include people diagnosed for at least four years who experience troublesome dyskinesia or “off” periods, even if they haven’t reached advanced stages.
How Dyskinesia Is Tracked
Neurologists use standardized rating scales to assess dyskinesia severity. The Unified Dyskinesia Rating Scale captures multiple dimensions: how the patient perceives the movements, how much time per day is affected, which body regions are involved, and how much the movements interfere with daily activities. This combination of patient-reported and clinician-observed data helps guide treatment decisions over time and gives a more complete picture than a brief office visit alone, since dyskinesia fluctuates throughout the day depending on medication timing.